Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification D Ruggero, S Grisendi, F Piazza, E Rego, F Mari, PH Rao, ...
Science 299 (5604), 259-262, 2003
495 2003 Involvement of the IP-10 chemokine in sarcoid granulomatous reactions C Agostini, M Cassatella, R Zambello, L Trentin, S Gasperini, A Perin, ...
The Journal of Immunology 161 (11), 6413-6420, 1998
233 1998 The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis L Trentin, C Agostini, M Facco, F Piazza, A Perin, M Siviero, C Gurrieri, ...
The Journal of clinical investigation 104 (1), 115-121, 1999
203 1999 Measurement of the Atlas Collaboration
arXiv preprint arXiv:1509.05276, 2015
187 * 2015 ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma GS Nowakowski, A Chiappella, RD Gascoyne, DW Scott, Q Zhang, ...
Journal of Clinical Oncology 39 (12), 1317, 2021
180 2021 Multiple myeloma cell survival relies on high activity of protein kinase CK2 FA Piazza, M Ruzzene, C Gurrieri, B Montini, L Bonanni, G Chioetto, ...
Blood 108 (5), 1698-1707, 2006
146 2006 Search for Higgs boson pair production in the two bottom quarks plus two photons final state in G Aad, B Abbott, DC Abbott, AA Abud, K Abeling, DK Abhayasinghe, ...
Physical Review D 106 (5), 052001, 2022
145 2022 The theory of APL F Piazza, C Gurrieri, PP Pandolfi
Oncogene 20 (49), 7216-7222, 2001
136 2001 Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways F Piazza, S Manni, M Ruzzene, LA Pinna, C Gurrieri, G Semenzato
Leukemia 26 (6), 1174-1179, 2012
127 2012 Direct constraint on the Higgs–charm coupling from a search for Higgs boson decays into charm quarks with the ATLAS detector G Aad, B Abbott, DC Abbott, AA Abud, K Abeling, DK Abhayasinghe, ...
The European Physical Journal C 82 (8), 717, 2022
125 2022 Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia A Teramo, C Gattazzo, F Passeri, A Lico, G Tasca, A Cabrelle, V Martini, ...
Blood, The Journal of the American Society of Hematology 121 (19), 3843-3854, 2013
116 2013 Search for new phenomena in events with two opposite-charge leptons, jets and missing transverse momentum in pp collisions at G Aad, B Abbott, DC Abbott, A Abed Abud, K Abeling, DK Abhayasinghe, ...
Journal of high energy physics 2021 (4), 1-62, 2021
111 2021 Search for charginos and neutralinos in final states with two boosted hadronically decaying bosons and missing transverse momentum in p p collisions at s= 13 TeV with the ATLAS … G Aad, B Abbott, DC Abbott, AA Abud, K Abeling, DK Abhayasinghe, ...
Physical Review D 104 (11), 112010, 2021
110 2021 ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2 ‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B … U Vitolo, TE Witzig, RD Gascoyne, DW Scott, Q Zhang, W Jurczak, ...
Hematological Oncology 37, 36-37, 2019
106 2019 Measurement of the c-jet mistagging efficiency in G Aad, B Abbott, DC Abbott, AA Abud, K Abeling, DK Abhayasinghe, ...
The European Physical Journal C 82 (1), 1-27, 2022
94 2022 Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of … S Manni, A Brancalion, E Mandato, LQ Tubi, A Colpo, M Pizzi, ...
PloS one 8 (9), e75280, 2013
93 2013 Self-ordered limit cycles, chaos, and phase slippage with a superfluid inside an optical resonator F Piazza, H Ritsch
Physical review letters 115 (16), 163601, 2015
92 2015 Measurements of Higgs boson production cross-sections in the Atlas Collaboration
arXiv preprint arXiv:2201.08269, 2022
91 2022 Search for new phenomena in G Aad, B Abbott, DC Abbott, AA Abud, K Abeling, DK Abhayasinghe, ...
Physical Review D 104 (11), 112005, 2021
90 2021 STAT3 mutation impacts biological and clinical features of T-LGL leukemia A Teramo, G Barilà, G Calabretto, C Ercolin, T Lamy, A Moignet, ...
Oncotarget 8 (37), 61876, 2017
87 2017 
Andrea Visentin, M.D.Ematologia e Immunologia Clinica, Università degli Studi di PadovaEmail verificata su aopd.veneto.it
